Home / Market News / $HCA
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Analyst Rating Updates for HCA Healthcare

Nov 18, 2026, 8:03 PM UTC · Primary ticker $HCA

This filing discloses updated analyst ratings and price targets for HCA Healthcare from JP Morgan and Mizuho Securities. While JP Morgan maintained a neutral rating, it significantly raised its price target, and Mizuho maintained a buy rating with a higher target. This indicates a generally positive sentiment from these analysts regarding HCA's valuation and future prospects.

JP Morgan maintained a neutral rating on HCA Healthcare but raised its price target by $50 to $475.00, while Mizuho Securities maintained a buy rating with a $570.00 price target. This indicates that despite one firm's neutral stance, both analysts see increased value in HCA Healthcare, with Mizuho's target being particularly bullish. This news is generally positive for HCA Healthcare investors, as it suggests a potential upside in the stock price based on expert analysis. For traders, this could signal short-term buying interest, though the long-term impact depends on broader market conditions and HCA's actual performance relative to these targets. The key opportunity lies in the potential for the stock to move towards these higher price targets.

$HCA positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.